Diarrhea
"Diarrhea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Descriptor ID |
D003967
|
MeSH Number(s) |
C23.888.821.214
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diarrhea".
Below are MeSH descriptors whose meaning is more specific than "Diarrhea".
This graph shows the total number of publications written about "Diarrhea" by people in this website by year, and whether "Diarrhea" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1983 | 1 | 0 | 1 | 1984 | 1 | 1 | 2 | 1985 | 3 | 0 | 3 | 1986 | 1 | 0 | 1 | 1987 | 1 | 0 | 1 | 1988 | 0 | 1 | 1 | 1989 | 2 | 0 | 2 | 1991 | 1 | 0 | 1 | 1992 | 0 | 1 | 1 | 1993 | 1 | 0 | 1 | 1994 | 1 | 1 | 2 | 1996 | 1 | 3 | 4 | 1997 | 0 | 1 | 1 | 1998 | 0 | 1 | 1 | 2000 | 1 | 2 | 3 | 2001 | 0 | 4 | 4 | 2002 | 4 | 3 | 7 | 2003 | 0 | 2 | 2 | 2004 | 2 | 4 | 6 | 2005 | 4 | 3 | 7 | 2006 | 3 | 3 | 6 | 2007 | 3 | 1 | 4 | 2008 | 2 | 4 | 6 | 2009 | 0 | 6 | 6 | 2011 | 2 | 3 | 5 | 2012 | 0 | 2 | 2 | 2013 | 4 | 5 | 9 | 2014 | 4 | 4 | 8 | 2015 | 2 | 2 | 4 | 2016 | 3 | 2 | 5 | 2017 | 3 | 2 | 5 | 2018 | 2 | 1 | 3 | 2019 | 2 | 5 | 7 | 2020 | 5 | 5 | 10 | 2021 | 2 | 2 | 4 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Diarrhea" by people in Profiles.
-
Cherny KE, Balaji A, Mukherjee J, Goo YA, Hauser AR, Ozer E, Satchell KJF, Bachta KER, Kochan TJ, Mitra SD, Kociolek LK. Identification of Clostridium innocuum hypothetical protein that is cross-reactive with C. difficile anti-toxin antibodies. Anaerobe. 2022 Jun; 75:102555.
-
Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
-
Cherny KE, Muscat EB, Reyna ME, Kociolek LK. Clostridium innocuum: Microbiological and clinical characteristics of a potential emerging pathogen. Anaerobe. 2021 Oct; 71:102418.
-
Miles-Jay A, Young VB, Pamer EG, Savidge TC, Kamboj M, Garey KW, Snitkin ES. A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microb Genom. 2021 06; 7(6).
-
Zemmour D, Charbonnier LM, Leon J, Six E, Keles S, Delville M, Benamar M, Baris S, Zuber J, Chen K, Neven B, Garcia-Lloret MI, Ruemmele FM, Brugnara C, Cerf-Bensussan N, Rieux-Laucat F, Cavazzana M, André I, Chatila TA, Mathis D, Benoist C. Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4+ T cell perturbations. Nat Immunol. 2021 05; 22(5):607-619.
-
Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
-
Rogers WS, Westblade LF, Soave R, Jenkins SG, van Besien K, Singh HK, Walsh TJ, Small CB, Shore T, Crawford CV, Satlin MJ. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020 10 23; 71(7):1693-1700.
-
Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN, Saraiya B, Pal SK, Stein MN, Mortazavi A. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
-
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 10 12; 38(4):489-499.e3.
-
Wolf DC, Wolf CH, Rubin DT. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 08; 115(8):1298.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|